We have revealed that knocking down SAMD9 expression levels in glioma cells decreased the glioblastoma cell progression via the AKT/PI3K pathway, but the detailed mechanism of how SAMD9 affected the occurrence of gliomas and its impact on tumor immunity has not been reported in gliomas (29). The gene discussed is AKT1; the disease is central nervous system cancer.